BioNTech to Acquire Biotheus to Boost Oncology Strategy - Yahoo …
1 day ago · Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential ...
BioNTech Boosts Oncology Strategy With $800 Million+ China …
1 day ago · With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
BioNTech to Acquire Biotheus for $800 Million to Expand …
1 day ago · BNTX. BioNTech SE (BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational ...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
1 day ago · BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition
7 hours ago · BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, ... Shares of BioNTech were up 4.9% on Nov. 13 following the announcement of the news.
BioNTech signs agreement to acquire Biotheus - Pharmaceutical …
14 hours ago · The deal is set for completion in Q1 2025. Credit: afotostock via Shutterstock. BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1 and vascular endothelial growth factor A-targeting bispecific antibody. This acquisition is set to align with BioNTech ...
Biotheus Enters Into Strategic Partnership with BioNTech to …
Jul 20, 2023 · PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations.
BioNTech Takes Aim at Keytruda With Potential $950M Biotheus Buy
1 day ago · According to Wednesday’s news release, BNT327/PM8002 has so far been administered to 700 patients across different trials and has demonstrated “encouraging efficacy and tolerability” in several tumor types. BioNTech plans to launch “multiple” registrational trials for BNT327/PM8002 in 2024 and 2025, assessing its combination with ...
BioNTech to Present Clinical Data Updates Across mRNA and ...
Sep 5, 2024 · BNT327/PM8002 is an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization for vascular normalization and immunostimulation in the microenvironment of the tumor.
Biotheus Enters Into Strategic Partnership with BioNTech to ... - BioSpace
Nov 6, 2023 · Biotheus Inc. (“Biotheus”) today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
- Some results have been removed